Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071 Publication February 17, 2016 Date: Pages: 109 Publisher: TechNavio Countries: Global [1] $3,000.00 Publication Type * - Select - Please choose the suitable license type from above. More details are at given under tab "Report License Types" below. Add to cart Pharma & Healthcare [2] Healthcare [3]
Therapeutic [4] Oncology [5] Description: Report forecast the global oncology biosimilars market to grow at a CAGR of 31.76% during the period 2016-2020. Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes. Global Oncology Biosimilars Market to grow at a CAGR of 31.76% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global oncology biosimilars market for the period 2016-2020. To calculate the market size, the report considers revenue generated from the sales of biosimilars used to treat cancer. The market is divided into the following segments based on geography: Americas APAC EMEA Global Oncology Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors Biocon Celltrion Dr. Reddy's Laboratories F. Hoffmann-La Roche Hospira Mylan
Sandoz Other prominent vendors AbbVie Allergan Amgen AstraZeneca Baxter Biogen BioXpress Therapeutics Boehringer Ingelheim Cipla Coherus BioSciences Coherus BioSciences Daiichi Sankyo Emcure Pharmaceuticals GlaxoSmithKline (GSK) Intas Pharmaceuticals Merck Pfizer Sanofi 3SBio Wockhardt Market driver Rise in number of patent expiries For a full, detailed list, view our report Market challenge Risks related to failure of drugs in the market For a full, detailed list, view our report Market trend Emergence of biosimilars For a full, detailed list, view our report
Key questions answered in this report What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst s time when you purchase this market report. Details are provided within the report. Table Of Contents: PART 01: Executive summary Highlights PART 02: Scope of the report Market overview Top-vendor offerings PART 03: Market research methodology Research methodology Economic indicators PART 04: Introduction Key market highlights PART 05: Overview of cancer Epidemiology Economic burden of cancer PART 06: Biosimilars industry Comparison between biosimilars and generic small molecules Factors influencing biologics and biosimilars Biosimilars: business and pricing strategy Factors affecting the uptake of biosimilars Biosimilar opportunities
Growth of biosimilars 2014 2020 Market penetration of originators and biosimilars in different regions Current and future trends in global oncology biosimilars market Challenges for new entrants PART 07: Global pharmaceutical market Market size and forecast Global biosimilars market PART 08: Market landscape Market overview Market size and forecast Five forces analysis PART 09: Market segmentation by end-user Hospitals Retail pharmacies PART 10: Market segmentation by application Cancer treatment drugs Supportive care drugs PART 11: Geographical segmentation Global oncology biosimilar drugs market by geographical segmentation 2015-2020 Oncology biosimilars market in EMEA Oncology biosimilars market in APAC Oncology biosimilars market in Americas PART 12: Key leading regions US Europe Japan India China PART 13: Market drivers Rise in number of patent expiries Increase in prevalence of cancer Growing aging population
Promising drug pipeline Need for cost-effective treatment Favorable government regulations PART 14: Impact of drivers PART 15: Market challenges Risks related to failure of drugs in market Multiple manufacturing complexities Reluctance among physicians to prescribe biosimilar products Complicated regulatory process Limited availability of biosimilar products Risk of side effects PART 16: Impact of drivers and challenges PART 17: Market trends Emergence of biosimilars Outsourcing of biosimilar manufacturing activities Rising number of strategic collaborations Increase in cancer awareness Rise in R&D PART 18: Vendor landscape Competitive scenario Biocon Celltrion Dr. Reddy's Laboratories F Hoffmann-La Roche Hospira Mylan Sandoz Other prominent vendors PART 19: Appendix List of abbreviations PART 20: Explore Technavio
List of Exhibits Exhibit 01: Product offerings Exhibit 02: Global biosimilars and oncology biosimilars market 2015 Exhibit 03: Cancer burden in European Union (EU) Exhibit 04: Global incidence of cancer 2015 Exhibit 05: Global mortality of cancer type 2015 Exhibit 06: Estimated numbers of cancer survivors by age in US 2014 Exhibit 07: Definition of biosimilars in different regions Exhibit 08: Comparison between biosimilars and generic small molecules Exhibit 09: Factors influencing biologics and biosimilars Exhibit 10: Impact of biosimilars cost savings on various sectors Exhibit 11: Factors affecting success of biosimilars Exhibit 12: Biosimilars industry: Point-of-view Exhibit 13: Factors affecting the uptake of biosimilars Exhibit 14: Strategic factors for new entrant Exhibit 15: Growth of biosimilars Exhibit 16: Share of biosimilars in recombinant drugs sales in major markets 2014 Exhibit 17: Trends in global oncology biosimilars market Exhibit 18: Challenges for new entrants Exhibit 19: Global pharmaceutical market 2015-2020 ($ trillions) Exhibit 20: Global biosimilars market 2015-2020 ($ billions) Exhibit 21: Number of approved biosimilars in regulated and semi-regulated markets Exhibit 22: Global pharmaceutical, biosimilars, and oncology biosimilars market 2015 ($ billions) Exhibit 23: Global oncology biosimilars market 2015-2020 ($ billions) Exhibit 24: Global oncology biosimilars market overview Exhibit 25: Five forces analysis Exhibit 26: Oncology biosimilars market segmentation by end-user 2014 Exhibit 27: Global oncology biosimilars segmentation by application Exhibit 28: Oncology biosimilars by application Exhibit 29: Global oncology biosimilars market by geographical segmentation 2015 Exhibit 30: Global oncology biosimilars market revenue by geography 2015-2020 ($ billions) Exhibit 31: Oncology biosimilars market in EMEA 2015-2020 ($ billions) Exhibit 32: Oncology biosimilars market in APAC 2015-2020 ($ billions) Exhibit 33: Oncology biosimilars market in Americas 2015-2020 ($ billions) Exhibit 34: Global oncology biosimilars market: YoY revenue and growth based on geography 2015-2020 ($ billions) Exhibit 35: Key leading regions Exhibit 36: Pharmaceutical R&D expenditure in US 2010-2015 ($ billions) Exhibit 37: Approvals of biologicals versus biosimilars via PHSA
Exhibit 38: Approval process for biosimilars in US Exhibit 39: Benefits of biosimilars to US healthcare system Exhibit 40: Role of stake holders Exhibit 41: SWOT analysis Exhibit 42: Oncology biosimilars approved by EMA in Europe Exhibit 43: Guidelines for biosimilars in EU Exhibit 44: Time line of biosimilars in Europe Exhibit 45: Key stake holders Exhibit 46: Key drivers and restraints Exhibit 47: Biosimilar industry challenges in Europe Exhibit 48: SWOT analysis Exhibit 49: Biosimilars approved by PMDA in Japan Exhibit 50: Review process for biosimilars in Japan Exhibit 51: Drivers and challenges in oncology biosimilars market in Japan Exhibit 52: SWOT analysis Exhibit 53: Biosimilars approved in India Exhibit 54: Timeline for development of biosimilars in India Exhibit 55: Challenges and strategies Exhibit 56: Major domestic and international vendors operating in India Exhibit 57: Drivers and challenges Exhibit 58: SWOT analysis Exhibit 59: Top domestic and international vendors operating in China Exhibit 60: Drivers and challenges Exhibit 61: SWOT analysis Exhibit 62: Patent expiries of oncology biologics in US and EU 2020 Exhibit 63: Global incidence of cancer 2015 and 2020 Exhibit 64: Impact of drivers Exhibit 65: Impact of drivers and challenges Exhibit 66: Global competitive landscape 2015 Exhibit 67: Biocon: Key takeaways Exhibit 68: Celltrion: Key takeaways Exhibit 69: Dr. Reddy's Laboratories: Key takeaways Exhibit 70: F. Hoffmann-La: Key takeaways Exhibit 71: Hospira: Key takeaways Exhibit 72: Mylan: Key takeaways Exhibit 73: Sandoz: Key takeaways Companies Mentioned: Biocon, Celltrion, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, Hospira, Mylan, Sandoz, AbbVie, Allergan, Amgen, AstraZeneca, Baxter, Biogen, BioXpress Therapeutics, Boehringer Ingelheim, Cipla, Coherus BioSciences, Coherus BioSciences, Daiichi Sankyo, Emcure Pharmaceuticals,
GlaxoSmithKline (GSK), Intas Pharmaceuticals, Merck, Pfizer, Sanofi, 3SBio,Wockhardt. License Types: Single User License (PDF) This license allows for use of a publication by one person. This person may print out a single copy of the publication. This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. This person cannot share the publication (or any information contained therein) with any other person or persons. Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Site License (PDF)* This license allows for use of a publication by all users within one corporate location, e.g. a regional office. These users may print out a single copy of the publication. These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased. Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Global License (PDF)* This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company. Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization. These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
*If Applicable. Source URL: https://www.marketresearchreports.com/technavio/global%c2%a0oncology%c2%a0biosimilarsmarket-2016-2020 Links [1] https://www.marketresearchreports.com/countries/global [2] https://www.marketresearchreports.com/pharma-healthcare [3] https://www.marketresearchreports.com/healthcare [4] https://www.marketresearchreports.com/therapeutic [5] https://www.marketresearchreports.com/oncology